Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00105950
First received: March 18, 2005
Last updated: August 29, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2008
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Publications:
Kaufman B, Wu Y, Amonkar M, Sherrill B, Bachelot T, Salazar V, Viens P, Johnston S. Impact of Lapatinib Monotherapy on Quality of Life and Pain Symptoms in Patients With HER2+ Relapsed or Refractory Inflammatory Breast Cancer. [Curr Med Res Opin]. 2010;26(5):1065-1073.